Why peptide prices vary so much

Synthesis cost scales worse than linearly with length. As set out in how research peptides are made, each residue requires a full coupling cycle and no cycle is perfectly efficient, so the proportion of chains carrying the complete correct sequence falls multiplicatively.

A 5-residue peptide and a 40-residue peptide are not two points on the same line. The longer one consumes more reagent per unit of product, requires more aggressive purification to remove a larger population of deletion sequences, and discards more material in the process.

Structural features beyond a plain linear chain each add steps:

• Disulfide bridges — an oxidation and refolding step, with purification of incorrectly paired isomers.
• Cyclisation — performed at high dilution to suppress intermolecular reaction, which means large solvent volumes for small product quantities.
• Lipidation or PEGylation — additional coupling and purification.
• Non-standard or D-amino acids — the building blocks themselves are considerably more expensive than the twenty standard residues.

A modified peptide of the same length as an unmodified one is a genuinely different manufacturing proposition.

This is the least visible driver and one of the largest. Purity is set by where the collection window is drawn across the preparative HPLC peak. Narrow window, higher purity, lower yield. Wide window, more product, more closely-related impurities carried through.

The difference between material specified at 95% and at 99% can be a substantial fraction of the batch discarded. That is a real cost, and a supplier selling the wider cut at a lower price is not necessarily doing anything improper — provided the specification is stated.

Per-batch analysis costs money per batch. A supplier running HPLC and mass spectrometry on every lot, retaining records, and providing lot-specific documentation on request carries a recurring cost that a supplier publishing one representative certificate does not.

It is a modest per-vial figure at volume, but it is not zero, and it is one of the differences hidden inside a price gap. Batch numbers and traceability covers what that spend actually buys.

Peptide synthesis has strong economies of scale. A compound made in kilogram quantities for a large market is dramatically cheaper per milligram than one made in gram quantities to order. Compounds that have attracted broad interest are cheap for this reason alone, independent of any quality difference.

Import route, storage, handling and the cost of operating in a particular jurisdiction also enter the price. A UK-held stock with domestic dispatch carries costs that a direct-from-manufacturer drop-ship does not — and offers a correspondingly different service.

Where a price sits far below the cluster, the difference is usually accounted for by something not being done:

• No per-batch testing — one certificate, reused indefinitely.
• A wider purification cut sold against a purity claim it was not measured to meet.
• No net peptide content determination, so the vial contains materially less peptide than the label implies while remaining technically accurate about its fill weight.
• Underfilling — nominal weight not verified.
• No storage discipline in the supply chain, so material arrives already partly degraded.

The last three are the ones that produce a product which appears equivalent and is not. None is detectable from a listing page; all are detectable from a lot-specific Certificate of Analysis, which is why the document is the thing worth asking for.

A price comparison is only meaningful per unit of actual peptide, on comparable specification. In practice that means:

1. Normalise to price per mg of peptide, not per vial.
2. Apply net peptide content where it is stated — and note the uncertainty where it is not.
3. Check the purity specification and the method, not just the headline percentage.
4. Establish whether documentation is lot-specific or generic.
5. Include delivery, storage condition on transit, and whether the stock is held domestically.

Done properly, most of the apparent tenfold spread in this market compresses considerably — and the part that does not compress is usually informative.